Retrospective Study of First-Line Chemotherapy with Monoclonal Antibodies in Patients 70 to 99 Years Old with Metastatic Colorectal Adenocarcinoma

What this Trial Is About

This research aims to observe treatments in patients aged 70 years or older who have metastatic colorectal adenocarcinoma and are receiving first-line therapy. It focuses on how chemotherapy combined with monoclonal antibodies is used in elderly patients, considering their age, general health, and tumour characteristics such as genetic mutations in RAS and BRAF. The study specifically collects data on patients treated with fixed-dose or reduced-dose chemotherapy doublets paired with full-dose monoclonal antibodies. Treatment strategies vary based on tumour site and mutations, with anti-VEGF therapy using Bevacizumab preferred for right-sided or mutated tumours and anti-EGFR antibodies like Panitumumab or Cetuximab for left-sided wild-type tumours. Due to frailty and risk of toxicity, full-dose doublet chemotherapy is often not feasible in elderly patients, so reduced doses or monochemotherapy combined with monoclonal antibodies are commonly used. This study retrospectively gathers case series data on these treatment approaches in patients aged 70 and older. Participants medical records are reviewed to assess outcomes such as neutropenia and diarrhea incidence over 24 months, along with progression-free survival and overall survival. Researchers also examine differences in toxicity between anti-VEGF and anti-EGFR monoclonal antibodies. The study collects information on patient condition, treatment type, and effectiveness markers during routine care without additional interventions, covering up to two years of follow-up.

COLON ERDERLY LOW DOSE